# Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy

> **NIH NIH R21** · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 2021 · $263,086

## Abstract

PROJECT SUMMARY
A series of recent studies have highlighted the importance of the composition of the gut microbiota as a factor
determining the efficacy of checkpoint inhibitor therapy to treat a variety of cancers. These studies have identified
a number of phylogenetically unrelated taxa that lack consistency across reports, generating confusion and
skepticism in the field. We evaluated the effect of prebiotics (inulin and mucin) and found that these treatments
induce alterations in gut microbiota composition and lead to tumor growth attenuation in some but not all of the
tumor models tested. Comparison of microbiota profiles of mice associated with effective tumor control to those
that failed to do so, suggests that bacterial species encoding anti-tumor phenotypes are enriched in a number of
distinct phylogenetic clades. Similarly, we observed that anti-tumor taxa are positively correlated with distinct
TILs profiles suggesting that an optimized bacterial cocktail capable of stimulating multiple anti-tumor immune
responses may allow more robust tumor growth control. We will test whether inulin feeding restores tumor control
of gnotobiotic mice colonized with fecal microbiota from patients that were non-responsive to checkpoint inhibitor
therapy. We are strongly positioned to engage in translational efforts to target the isolation and validation of
relevant phylogenetic groups to identify taxa promoting improved responsiveness to checkpoint inhibitors as an
important step toward developing optimized probiotic formulations for use in human patients. We will explore
mechanistic aspects of inulin's ability to confer anti-tumor immunity we will conduct metabolomics analyses using
gnotobiotic mice colonized with defined, low-complexity communities and in vitro cultures to identify inulin-
dependent metabolites that may signal the gut immune system to induce anti-tumor immunity.

## Key facts

- **NIH application ID:** 10128089
- **Project number:** 1R21CA249822-01A1
- **Recipient organization:** SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- **Principal Investigator:** Hyungsoo Kim
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $263,086
- **Award type:** 1
- **Project period:** 2021-05-17 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10128089

## Citation

> US National Institutes of Health, RePORTER application 10128089, Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy (1R21CA249822-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10128089. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*